

Diary No. 4977 dated
12.02.2018

F. No. 12-38/15-DC (Pt. C)
Government of India

Tele No.011-23236965
Fax.No.011-23236973

Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated:

26 FEB 2020

To
M/s Ajanta Pharma Limited,
Ajanta House, Charkop,
Kandivali West,
Mumbai - 400 067, India.

Subject:- Permission for conducting clinical study entitled, "A multicentric, randomized, double blind, parallel group, comparative, Phase - III clinical study to evaluate the efficacy, safety and tolerability of Azelnidipine 8mg plus Telmisartan 40mg and Azelnidipine 16mg plus Telmisartan 40mg Tablets versus Azelnidipine Tablets 16mg and Telmisartan Tablets 40mg monotherapy in subjects with Stage 2 Hypertension" - regarding.

Sir,

With reference to your Application No. APL/DRA/DCGI/18/98 dated 08.02.2018, please find enclosed herewith the permission in **Form CT-06, No. CT/ND/14/2020** to conduct the subject mentioned clinical trial under the provisions of **New Drugs and Clinical Trial Rules, 2019.**

This permission is subject to the conditions, as mentioned below.

Yours faithfully



(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licensing Authority

Condition of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics

Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with

the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.



FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL
NEW DRUG**

The Central Licensing Authority hereby permits M/s Ajanta Pharma Limited, Ajanta House, Charkop, Kandivali-West, Mumbai - 400 067, India to conduct clinical trial of the new drug or investigational new drug as per protocol number **Protocol No. APL/CT/17/13, Version No. 00, Dated 30.10.2017** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or investigational new drug:	Azelnidipine 8mg/ 16mg + Telmisartan 40mg/ 40mg	
Therapeutic class:	Antihypertensive	
Dosage form:	Tablet	
Composition:	Each tablet contains: Azelnidipine 8mg/16mg + Telmisartan 40mg/40mg	
Indications:	For the treatment of Stage - II hypertension.	
Details of clinical trial sites-		
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
1.	Mr. Vivek Kumar, King George's Medical University, Lucknow -226003	Institutional Ethics Committee, Office of research cell, Administrative Block, King George's Medical University, Lucknow-226003, Uttar Pradesh, India ECR/262/Inst/UP/2013/RR-16
2.	Dr. Barama Srihari, Dept. Of cardiology Osmania Medical College & General Hospital , Afzalgunj, Hyderabad, T.S. -500012, I	Institutional Ethics Committee, Osmania Medical College, Koti, Hyderabad-500095, Telangana State, India ECR/300/Inst/AP/2013/RR-16
3.	Dr. Darivemula Anil Kumar, Department of General Medicine, Gandhi Hospital, Musheerabad, Secunderabad, Telangana	Institutional Ethics Committee, Gandhi Medical College/ Gandhi Hospital, Musheerabad, Secunderabad-500019 ECR/180/Inst/AP/2013/RR-16
4.	Dr. Indira Pattnaik, Sparsh Hospital and Critical care (P) Ltd, Plot No. A/407, Sahid Nagar Bhubaneshwar-751007, Odisha, India	Institute Ethics Committee, Sparsh Hospital and critical care (P) Ltd Plot No. A/407, Sahid Nagar, Bhubaneshwar-751007, Odisha, India ECR/68/Inst/OR/2013/RR-16
5.	Dr. Subrata H, Department of Medicine, 4 th Floor, Ronald Ross Building, IPGME & R and SSKM hospital, 44, AJC Bose Road Kolkata-700020	Ethics Committee IPGME & R Research Oversight committee, Institute of Postgraduate Medical education & Research, office of the Dean, College Building 5 th floor, 244, Acharya J.C. Bose Road, Kolkata-700030, India ECR/35/Inst/WB/2013/RR-16

6.	Dr. Prajapati Vipul Kumar Bacubhai, GCS Medical College, Hospital and Research Centre, Opp. DRM office, Nr. Chamunda Bridge, Naroda Road, Ahmedabad -380025 Gujarat, India	Institutional Ethics Committee, GCS Medical College, Hospital & Research centre, opp. DMR office, Nr. Chamunda Bridge, Naroda Road, Ahmedabad-380025 Gujarat, India ECR/339/Inst/GJ/2013/RR-16
7.	Dr. Brij Mohan Goyal, Apex Hospital Pvt. Ltd, SP 4 & 6 Malviya Industrial Area, Malviya Nagar, Jaipur – 302017 Rajasthan, India	Institutional Ethics Committee, Apex Hospital private limited, SP4 & 6, Malviya Nagar, Jaipur-30201, Rajasthan, India ECR/380/Inst/RJ/2013/RR-16
8.	Dr. Deepak Gupta, Barala Hospital & Research Centre radhaswami Bagh, NH-11, Jaipur Road, chomu-302017	Institutional Ethics Committee, Barala Hospital & Research Center, Radhaswami Bagh NH-11, Jaipur Road, Chomu-303702, Rajasthan, India ECR/838/Inst/RJ/2016
9.	Dr. Hrishikesh Bora, Down Town Hospital, Dispur, G.S Road, Guwahati-781006	Ethics Committee, Down Town Hospital, 6 th floor, 1 st Building, G.S. Road, Dispur, Guwahati-781006 Assam, India ECR/549/Inst/AS/2014/RR-16
10.	Dr. Manish Agarwal, Medilink Hospital Research Centre, basement Medilink Hospital , Nr. Shyamal Cross Road, 132 ft. Ring Road, Satellite, Ahmedabad -380015	Medilink Diagnostics Nr. Shyamal cross road, 132 ft. Ring Road, Satellite, Ahmedabad-3800015, Gujarat, India ECR/344/Inst/GJ/2013/RR-16
11.	Dr. Mukund Anant Deshpande, Department of Cardiology, Government Medical College and super Speciality Hospital, Tukdoji Square, Near Hanuman Nagar, Nagar-4400 09, Maharastra, India	Institutional Ethics Committee, Government Medical College, Nagpur, India ECR/43/Inst/MH/2013/RR-16
12.	Dr. Pankaj J. Akholkar, Department of Medicine, GMERS Medical College & Civil Hospital, Near New Gujarat High court, Sola, Ahmedabad-380061, Gujarat, India.	Institutional Ethics Committee, GMERS Medical College, Sola, S.G Highway Near New Gujarat Highway, Near New Gujarat High court, Ahmedabad-380061, Gujarat, India ECR/404/Inst/GJ/2013/RR-16

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.



(Dr. V. G. Somani)
Central Licensing Authority

Stamp

Dr. V. G. SOMANI
Drugs Controller General (India)
Dte. General of Health Services
Ministry of Health and Family Welfare
FDA Bhawan, Kotla Road, I.T.O.
New Delhi-110002

CT/ND/14/2020

New Delhi
Date: 26 FEB 2020